What to Expect From Johnson & Johnson’s Q3 2025 Earnings Report

Core Insights - Johnson & Johnson (JNJ) is a leading healthcare company with a market cap of $428 billion, focusing on pharmaceuticals, medical technologies, and consumer health products, and is set to announce its fiscal Q3 earnings for 2025 on October 14 [1] Financial Performance - Analysts project JNJ to report a profit of $2.78 per share for Q3 2025, reflecting a 14.9% increase from $2.42 per share in the same quarter last year [2] - For fiscal 2025, JNJ is expected to report a profit of $10.86 per share, an 8.8% increase from $9.98 per share in fiscal 2024, with further growth anticipated to $11.37 in fiscal 2026 [3] Stock Performance - Over the past 52 weeks, JNJ shares have increased by 10.7%, lagging behind the S&P 500 Index's 15.4% rise but outperforming the Health Care Select Sector SPDR Fund's 12.1% decline [4] - Following a strong Q2 performance, JNJ shares surged 6.2%, with overall revenue growing 5.8% year-over-year to $23.7 billion, exceeding consensus estimates by 3.8% [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for JNJ, with 11 out of 25 analysts recommending "Strong Buy," 2 suggesting "Moderate Buy," and 12 advising "Hold." The mean price target is $180.54, indicating a 1.6% potential upside from current levels [6]